Navigation Links
FDA Accords Priority Review For Pediatric Crohn's Disease Drug

The U.S. Food and Drug Administration (FDA) has decided to accord a priority review for the drug REMICADE (R) (infliximab) to be used in the treatment of pediatric// Crohn's disease, the drug's manufacturer Centocor, Inc. announced today. Crohn's disease affects the gastrointestinal tract and causes diarrhea, fever, abdominal pain and weight loss. As of now there is no drug to treat children who develop this condition. Centocor had filed a supplemental Biologics License Application (sBLA), which was accepted by the FDA.

The filing is based primarily on Phase 3 study results showing the unprecedented efficacy of REMICADE in the treatment of children with moderately to severely active Crohn's disease. In the REACH (a Randomized, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Anti-TNF Monoclonal Antibody REMICADE in Pediatric Subjects with Moderate to Severe Crohn's Disease) trial, nearly 90 percent (88.4 percent) of pediatric patients with moderately to severely active Crohn's disease who had an inadequate response to conventional therapy achieved clinical response at week 10 when treated with REMICADE. Nearly two-thirds (63.5 percent) of the patients who were randomized to treatment with REMICADE every 8 weeks were in clinical response at one year. Additionally, more than half of the patients treated with REMICADE every 8 weeks were in clinical remission at the end of one year.

"We are extremely pleased by the results of the REACH trial and by the FDA's decision to accept the application with a Priority Review," said Jerome A. Boscia, MD, Senior Vice President, Clinical Research and Development, Centocor, Inc. "REMICADE, if approved for the treatment of pediatric Crohn's disease, would represent a major advancement for children with this serious condition. We look forward to working closely with the FDA as it reviews these data for approval."

Priority Review is granted by the FDA to products that are considered to be a potential therapeutic advance over current therapies. Acceptance of the sBLA filing does not mean that a license has been issued for this indication nor does it represent any evaluation of the adequacy of the data submitted in the sBLA. REMICADE was FDA-approved in 1998 as the first biologic treatment for adults with moderate to severe Crohn's disease. In September 2005, REMICADE also became the first approved biologic treatment for moderate to severe ulcerative colitis (UC), making it the only biologic indicated for the treatment of both types of inflammatory bowel disease (IBD) in adults. Contact: Michael Parks 215-983-8000 Centocor, Inc. Source: Eurekalert
'"/>




Related medicine news :

1. British MPs Say Prostate Cancer Receives Low Priority in the NHS
2. Funds Pumped In To Reduce Waiting List of Priority Patients
3. Children Health Care To Be Given Priority
4. Hypertension Not Given Priority during Treatment
5. Healthcare And Education Top Most Priority Of The Govt: Nitish
6. Global Health Issues To Take Priority In The Current G8 Summit In Russia
7. Consistent National Standards For Assessment Of Overseas Trained Doctors A Priority
8. Women and Children Issues Should Get Priority in India
9. WHO Urges Higher Priority for Neglected Diseases
10. COAG Must Make Combating Severe Allergies A National Priority
11. Priority Needs to Be Given to Maternal Health in Afghanistan
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... 2017 , ... “Emotions are sacred, valid, honored, encouraged. This is the memo ... Generation Mindful. To help change the mindset of parents and educators from punitive to ... the Time-In Toolkit, which launched on Kickstarter 3 weeks ago and fully funded in ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that ... its marketing efforts with its product now available through Jet.com. , After 25 ... The effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... “Our Mountains ... potent tale of a couple that grew stronger together through the faith they shared ... Faith Through Trials” is the creation of published author, Barbara J. Corcoran, a retired ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Beyond Our Imaginations: ... life. “Beyond Our Imaginations: The Infinite God” is the creation of published author, Mark ... the country. , Lawrence shares, “The problem with becoming a greater man of God ...
(Date:8/18/2017)... , ... August 18, 2017 , ... “Kingdom Mandate for ... the Kingdom. “Kingdom Mandate for Kingdom Builders” is the creation of published author, ... moved to Eastern Europe as a missionary in 1983. He spent three decades ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s ... ended June 30, 2017.  All comparisons, unless otherwise noted, are ... Second Quarter 2017 Highlights include: ... million, an increase of 3.5% Total prescriptions ... margin of 7.5% versus 7.6% Gross ...
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
(Date:8/3/2017)...  Opioid addiction and other drugs of abuse, blood ... threatening outcomes, were problems taken on directly as laboratory ... support them, met this week. This according to Kalorama ... of abuse, procalcitonin and acute kidney injury were key ... meeting in San Diego, CA. ...
Breaking Medicine Technology: